clinical observation of icotinib hydrochloride for patients with advanced non small cell lung cancer

• DOI: 10.3760/cma.j.issn.0253-3766.2012.08.016
• Publication Date: 2012-08-01
• Authors: Shu-cai Zhang; Xi Li; Quan Zhang; Hui Zhang; Yi-fen Sun; Yuhua Wu; Xinjie Yang; Jia-lin Lü; Na Qin
• Keywords: Adult; Aged, 80 and over; Diarrhea; Male; Lung Neoplasms; Antineoplastic Agents; Exons; Exanthema; Middle Aged; ErbB Receptors; 03 medical and health sciences; 0302 clinical medicine; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Mutation; Disease Progression; Quinazolines; Humans; Female; Aged; Follow-Up Studies; Neoplasm Staging

To explore the efficacy and side effects of icotinib hydrochloride in the treatment of patients with advanced non-small cell lung cancer (NSCLC).The efficacy and side effects of icotinib hydrochloride in treatment of 59 cases with stage IV NSCIC and followed-up from March 2009 to January 2012 were retrospectively analyzed.Twenty seven patients (45.8%) showed partial response (PR), 17 patients (28.8%) achieved SD, and 15 (25.4%) had progressive disease. The objective response rate (ORR) was 45.8% (27/59), and disease control rate (DCR) was 74.6% (44/59). Among the 23 patients with EGFR mutation, ORR was 73.9% (17/23), and DCR was 95.7% (22/23). Thirty six patients (61.0%) achieved remission of symptoms to varying degrees. The main symptoms relieved were cough, asthmatic suffocating, pain and hoarseness. The major adverse events were mild skin rash (35.6%) and diarrhea (15.3%). Others were dry skin, nausea and stomach problems. The efficacy of icotinib hydrochloride were related to the ECOG performance status, smoking history, EGFR mutation and rash significantly (P < 0.05).Monotherapy with icotinib hydrochloride is effective and tolerable for patients with advanced NSCLC, especially with EGFR mutation.